IN THE HOUSE OF REPRESENTATIVES
August 4, 2017
Referred to the Committee on Energy and Commerce
To strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.
This Act may be cited as the
Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017 or the
BENEFIT Act of 2017.
Strengthening the use patient-experience data within benefit-risk framework
Section 569C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–8c) is amended—
in subsection (a)(1)—
in subparagraph (A), by striking
; and and inserting a semicolon;
in subparagraph (B), by striking the period and inserting
; and; and
by adding at the end the following:
as part of the risk-benefit assessment framework in the new drug approval process described in section 505(d), considering relevant patient-focused drug development data, such as data from patient preference studies (benefit-risk), patient reported outcome data, or patient experience data, developed by the sponsor of an application or another party.
in subsection (b)(1). by inserting
, including a description of how such data and information were considered in the risk benefit assessment described in section 505(d) before the period.
Passed the Senate August 3, 2017.
Julie E. Adams,